IP Library Granted Patent US 10,329,236
Granted Patent B2
US 10,329,236 · App. 15/696,448 · Granted Jun 25, 2019

Procedure for the preparation of 4-phenyl butyrate and uses thereof

Inventors: Huai-Chueh Chang (Tower Lakes, IL); Steven S. Pfeiffer (Camarillo, CA); Vasilios H. Iskos (Chicago, IL); Maki Uragami (Bethlehem, PA); Steven Weissman (Short Hills, NJ); Andrew Thompson (Mountainside, NJ)
Assignee: Horizon Therapeutics, LLC
C07C69/616C07C51/29C07C51/60C07C57/30C07C67/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,329,236
App. No.
15/696,448
Granted
Jun 25, 2019
Kind
B2
Abstract

Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.

Claims (9)

1. A pharmaceutical composition consisting of glycerol triphenylbutyrate having the structure:

wherein the glycerol triphenylbutyrate has a purity that is greater than about 99% by high performance liquid chromatography (HPLC) analysis,

less than 0.1% of any single individual impurity w/w as measured by area percentage of HPLC; and

less than 0.04% 3-benzoyl propionic acid w/w as measured by area percentage of HPLC.

2. A method of treating a patient with a nitrogen retention disorder, comprising administering to the patient the pharmaceutical composition of claim 1 .

3. The method of claim 2 , wherein the nitrogen retention disorder is a urea cycle disorder.

4. The method of claim 2 , wherein the patient is a pediatric subject under the age of 12.

5. The method of claim 2 , wherein the composition is administered orally.

6. The method of claim 2 , wherein the composition is administered by nasogastric tube or gastrostomy tube.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Dec 21, 2023
From: HORIZON THERAPEUTICS, LLC; HORIZON ORPHAN LLC
To: HORIZON THERAPEUTICS U.S. HOLDING LLC
Reel/Frame 065928/0608 →
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.); HZNP LIMITED; HORIZON THERAPEUTICS U.S. HOLDING LLC (SUCCESSOR IN INTEREST TO HORIZON THERAPEUTICS, LLC)
Reel/Frame 065154/0075 →
SECURITY AGREEMENT Recorded Oct 24, 2018
From: HORIZON PHARMA RHEUMATOLOGY LLC; HZNP LIMITED; HORIZON THERAPEUTICS, LLC
To: CITIBANK, N.A.
Reel/Frame 047720/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2017
From: CHANG, HUAI-CHUEH; PFEIFFER, STEVEN S.; ISKOS, VASILIOS H.; URAGAMI, MAKI; WEISSMAN, STEVEN; THOMPSON, ANDREW
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 043565/0746 →
Continuity (2)
Continuation 15164126 · May 25, 2016
Related Publication 20170362160A1 · Dec 21, 2017